Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
www.ncbi.nlm.nih.gov/pmc/articles/PMC10119362/
1 Users
0 Comments
1 Highlights
0 Notes
Tags
Top Highlights
Lecanemab’s preferential and strong binding to Aβ protofibrils may explain the difference in clinical efficacy and lower ARIA-E frequency
Ready to highlight and find good content?
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.